Abraham Getachew Kelbore | Deramtology | Innovative Research Award

Posted on by Skincare

Innovative Research Award

Abraham Getachew Kelbore – Wolaita Sodo University

Abraham Getachew Kelbore
Affiliation Wolaita Sodo University
Country Ethiopia
Scopus ID 56798540800
Documents 3024
Citations 3072
h-index 12
Subject Area Dermatology
Event World Skincare Innovation Awards
ORCID 0000-0001-9540-8671

Abraham Getachew Kelbore is an academic researcher and assistant professor specializing in tropical dermatology at Wolaita Sodo University, Ethiopia. His scholarly work focuses on skin diseases, neglected tropical diseases, and quality-of-life studies among dermatology patients. Through clinical research and community engagement, he has contributed to improving dermatological care in underserved regions. His research profile demonstrates active international collaboration and sustained scientific productivity.[1]

Abstract

This article summarizes the scholarly achievements of Abraham Getachew Kelbore in dermatology and tropical medicine. His research emphasizes evidence-based interventions, epidemiology of skin diseases, and healthcare accessibility in Ethiopia. The body of work demonstrates multidisciplinary collaboration and international visibility in peer-reviewed literature. These contributions support recognition within global dermatological research communities.[2]

Keywords

Dermatology, Tropical Medicine, Atopic Dermatitis, Skin Diseases, Ethiopia, Public Health, Neglected Tropical Diseases.

Introduction

Research in dermatology contributes significantly to disease prevention and quality-of-life improvement. Abraham Getachew Kelbore has focused on tropical skin disorders and healthcare delivery in resource-limited settings. His work bridges clinical practice, research, and community health initiatives. Such contributions align with broader public health priorities in Africa and beyond.[3]

Research Profile

Kelbore serves as Assistant Professor of Dermatology at Wolaita Sodo University and has extensive teaching experience. His interests include atopic dermatitis, neglected tropical diseases, and dermatological epidemiology. He has collaborated with international institutions and contributed to expanding dermatology services. His academic record reflects continued engagement in research and clinical innovation.[1]

Research Contributions

Major contributions include studies on atopic dermatitis, scabies prevalence, cutaneous leishmaniasis, and HIV-related skin disorders. His research has informed clinical practice and strengthened disease surveillance efforts. Several studies emphasize healthcare access and patient quality of life. These works demonstrate measurable relevance to global dermatology research.[4]

Publications

  • Impact of Atopic Dermatitis on the Quality of Life of Children in Ethiopia (2026).
  • The impact of atopic dermatitis on caregivers’ quality of life in Ethiopia (2025).
  • Atopic dermatitis in Ethiopian children: multicenter study (2024).
  • Scabies prevalence among prisoners in southern Ethiopia (2023).
  • Pattern of skin diseases in children attending dermatology clinics (2019).

Research Impact

The researcher’s publications have contributed to evidence generation in dermatology and public health. Citation metrics and international collaborations indicate growing academic influence. His work supports healthcare policy development and clinical decision-making in tropical settings. The research outputs remain relevant to practitioners and scholars worldwide.[5]

Award Suitability

The research profile demonstrates sustained productivity, international engagement, and societal relevance. Contributions to neglected tropical diseases and dermatology services illustrate measurable public health impact. These characteristics align with criteria commonly used for innovation and research awards. Recognition through the World Skincare Innovation Awards would acknowledge such achievements.

Conclusion

Abraham Getachew Kelbore has established a significant research presence in dermatology and tropical medicine. His scientific contributions address pressing healthcare challenges in Ethiopia and internationally. Continued scholarship and collaboration may further strengthen dermatological research capacity. The academic record supports professional recognition in global research forums.

External Links

References

  1. Kelbore, A. G., Enbiale, W., van Wyk, J. M., Bogino, E. A., Morrone, A., & Mosam, A. (2026). Impact of atopic dermatitis on the quality of life of children in Ethiopia: A multicenter prospective cohort study. Children. 
    https://doi.org/10.3390/children13020201
  2. Kelbore, A. G., Enbiale, W., van Wyk, J. M., & Mosam, A. (2024). Atopic dermatitis in Ethiopian children: A multicenter study of clinical severity, characteristics, and sociodemographic factors. Frontiers in Medicine. 
    https://doi.org/10.3389/fmed.2024.1410310
  3. Bogino, E. A., Beebe, N., Woldegeorgis, B. Z., Wondewosen, L., Dessu, B. K., Obsa, M. S., … & Kelbore, A. G. (2023). Scabies prevalence and its associated factors among prisoners in southern Ethiopia: An institution-based analytical cross-sectional study. PLOS Neglected Tropical Diseases. 
    https://doi.org/10.1371/journal.pntd.0011826
  4. Kelbore, A. G., Enbiale, W., Mosam, A., & van Wyk, J. M. (2022). Mapping research evidence on quality of life in children with atopic dermatitis in sub-Saharan Africa: A scoping review protocol. Systematic Reviews. 
    https://doi.org/10.1186/s13643-022-02133-w
  5. Kelbore, A. G., Owiti, P., Reid, A. J., Bogino, E. A., Wondewosen, L., & Dessu, B. K. (2019). Pattern of skin diseases in children attending a dermatology clinic in a referral hospital in Wolaita Sodo, southern Ethiopia. BMC Dermatology, 19, Article 8. 
    https://doi.org/10.1186/s12895-019-0085-5

Anastasia Orekhova | Fungal Infection | Young Scientist Award

Posted on by Skincare

Young Scientist Award

Anastasia Orekhova – National Medical Research Center for Therapy and Preventive Medicine

Anastasia Orekhova
Affiliation National Medical Research Center for Therapy and Preventive Medicine
Country Russia
Scopus ID 57201123629
Documents 115
Citations 128
h-index 7
Subject Area Fungal Infection
Event World Skincare Innovation Awards
ORCID 0000-0001-5887-2563

Anastasia Orekhova is a researcher whose scholarly activities focus on fungal infections, microbial biology, and the development of innovative approaches for antifungal treatment and diagnostic applications. Her academic record reflects sustained contributions to microbiology and biomedical sciences, particularly in studies involving Aspergillus species, Candida-related investigations, and nanoparticle-assisted therapeutic strategies.[1]

Abstract

This article presents an overview of Anastasia Orekhova’s scientific profile and research achievements in fungal infection studies. Her work encompasses pathogen biology, antifungal compounds, nanoparticle delivery systems, and diagnostic methodologies relevant to microbiological research. Through peer-reviewed publications and collaborative investigations, she has contributed to the advancement of knowledge concerning medically significant fungi and related therapeutic approaches.[2]

Keywords

Fungal Infection, Microbiology, Aspergillus, Candida, Antifungal Therapy, Nanoparticles, Biomedical Research, Diagnostic Applications.

Introduction

Research involving fungal pathogens has become increasingly important due to the clinical burden associated with invasive and opportunistic infections. Anastasia Orekhova’s studies have focused on understanding fungal mechanisms and evaluating novel strategies for treatment and detection. Her multidisciplinary research integrates microbiology, molecular science, and biomedical innovation to address challenges associated with fungal diseases.[3]

Research Profile

According to publicly available academic profiles, Orekhova has been associated with research institutions in Russia and Italy and has participated in studies related to infectious diseases and microbiology. Her scholarly output includes articles indexed in international databases and contributions addressing fungal physiology, extracellular enzymes, and therapeutic technologies.[1]

Research Contributions

  • Investigation of nanoparticle-based antifungal delivery systems.
  • Research on Aspergillus proteases and their biological activity.
  • Studies evaluating anti-Candida compounds and natural products.
  • Development of methodologies relevant to plasma protein analysis and fungal diagnostics.

Publications

Selected publications include investigations on Botrytis cinerea control through nanoparticle vectors, Aspergillus-targeted antifungal formulations, extracellular fungal proteases, and anti-Candida activity assessments. These studies have appeared in journals such as Scientific Reports, Molecules, Life, Natural Product Research, and Moscow University Biological Sciences Bulletin.[2]

Research Impact

The research portfolio demonstrates measurable scholarly engagement through indexed publications, citations, and interdisciplinary collaborations. Her investigations contribute to the broader understanding of fungal pathogenesis and support the development of evidence-based therapeutic and diagnostic approaches. Such contributions are relevant to both academic research and potential clinical applications.[4]

Award Suitability

Based on her documented publication record, research productivity, and contributions to fungal infection studies, Anastasia Orekhova demonstrates characteristics commonly associated with emerging scientific leadership. Her involvement in innovative investigations and peer-reviewed scholarship aligns with the objectives of the Young Scientist Award presented through the World Skincare Innovation Awards platform.[5]

Conclusion

Anastasia Orekhova has established a research profile centered on fungal microbiology and biomedical innovation. Through studies involving antifungal agents, nanoparticle technologies, and diagnostic methodologies, she has contributed to scientific understanding within her field. Her academic activities provide a foundation for continued research and recognition within the international scientific community.

References

  1. De Angelis, G., Simonetti, G., Chronopoulou, L., Orekhova, A., Badiali, C., Petruccelli, V., Portoghesi, F., D’Angeli, S., Brasili, E., & Pasqua, G. (2022). A novel approach to control Botrytis cinerea fungal infections: Uptake and biological activity of antifungals encapsulated in nanoparticle-based vectors. Scientific Reports, 12, Article 7286.
    https://doi.org/10.1038/s41598-022-11533-w
  2. Orekhova, A., Palocci, C., Chronopoulou, L., De Angelis, G., Badiali, C., Petruccelli, V., D’Angeli, S., Pasqua, G., & Simonetti, G. (2022). Poly-(lactic-co-glycolic) acid nanoparticles entrapping pterostilbene for targeting Aspergillus section Nigri. Molecules, 27(17), 5424.
    https://doi.org/10.3390/molecules27175424
  3. Osmolovskiy, A. A., Schmidt, L., Orekhova, A. V., Komarevtsev, S. K., Kreyer, V. G., Shabunin, S. V., & Egorov, N. S. (2021). Action of extracellular proteases of Aspergillus flavus and Aspergillus ochraceus micromycetes on plasma hemostasis proteins. Life, 11(8), 782.
    https://doi.org/10.3390/life11080782
  4. Cairone, F., Simonetti, G., Orekhova, A., Casadei, M. A., Zengin, G., & Cesa, S. (2021). Health potential of Clery strawberries: Enzymatic inhibition and anti-Candida activity evaluation. Molecules, 26(6), 1731.
    https://doi.org/10.3390/molecules26061731
  5. De Vita, D., Messore, A., Toniolo, C., Frezza, C., Scipione, L., Bertea, C. M., Micera, M., Di Sarno, V., Madia, V. N., Pindinello, I., & Orekhova, A. (2021). Towards a new application of amaranth seed oil as an agent against Candida albicans. Natural Product Research, 35(24), 5758–5762.
    https://doi.org/10.1080/14786419.2019.1696335

Sophia Hatziantoniou | Encapsulation techniques for active ingredients | Excellence in Research Award

Posted on by Skincare

Dr. Sophia Hatziantoniou | Encapsulation techniques for active ingredients | Excellence in Research Award

Department of Pharmacy, University of Patras, Greece

Dr. Sophia Hatziantoniou is an accomplished pharmaceutical scientist and Associate Professor at the Department of Pharmacy, University of Patras, specializing in pharmaceutical technology, nanotechnology, topical cosmetics, and advanced drug delivery systems. Her influential investigations in liposomal formulations, nanoemulsions, dendrimer technologies, and anticancer therapeutics have earned wide scientific recognition. With an h-index of 36 and more than 4,400 citations, she has contributed significantly to pharmaceutical nanoscience and biomedical innovation. Her interdisciplinary research integrates nanomedicine, pharmaceutics, and biotechnology to develop novel therapeutic approaches with enhanced clinical effectiveness. Through impactful publications, collaborative projects, and scientific mentorship, Dr. Hatziantoniou continues advancing pharmaceutical sciences while supporting innovative healthcare solutions and translational biomedical research worldwide.

Professional Profile

Education

Dr. Sophia Hatziantoniou developed a strong academic background in pharmaceutical sciences, pharmaceutics, and nanotechnology through advanced higher education and specialized scientific training. Her educational foundation enabled extensive expertise in drug delivery systems, biomaterials, topical formulations, and cancer therapeutics. She cultivated multidisciplinary scientific skills integrating chemistry, biotechnology, pharmaceutical engineering, and biomedical sciences to support innovative healthcare applications. Her academic preparation strengthened her ability to investigate nanoformulations, liposomal carriers, and pharmaceutical nanotechnology for therapeutic improvement. Throughout her scholarly development, she demonstrated dedication to scientific excellence, evidence-based experimentation, and translational pharmaceutical research. Her educational achievements have contributed significantly to her professional growth as a respected academic researcher and mentor in pharmaceutical technology and biomedical innovation.

Professional Experience

Dr. Hatziantoniou has established an impressive professional career as an academic researcher, pharmaceutical scientist, and Associate Professor within the Department of Pharmacy at the University of Patras. She possesses extensive experience in pharmaceutical technology, nanomedicine, topical therapeutics, and anticancer drug delivery systems. Her professional activities include scientific supervision, collaborative biomedical projects, advanced pharmaceutical investigations, and mentoring emerging researchers in nanotechnology-based therapeutics. She has participated in numerous interdisciplinary studies exploring liposomes, nanoemulsions, dendrimers, and controlled-release formulations. Through continuous engagement with international scientific communities, she has contributed to the advancement of pharmaceutics and biomedical innovation. Her long-standing academic and research experience reflects exceptional dedication toward improving therapeutic technologies and healthcare-related scientific progress.

Research Interest

Dr. Sophia Hatziantoniou’s research interests primarily focus on pharmaceutical nanotechnology, advanced drug delivery systems, topical formulations, liposomal therapeutics, and cancer-targeted nanomedicine. Her investigations emphasize nanoformulations designed to improve drug bioavailability, therapeutic effectiveness, controlled release behavior, and biomedical compatibility. She actively explores lipid-based carriers, dendrimer technologies, nanoemulsions, and nanoparticle engineering for pharmaceutical and cosmetic applications. Her scientific work also examines anticancer compounds, curcumin derivatives, vaccine-related pharmaceutical safety, and biomaterial interactions within biological systems. By integrating pharmaceutical sciences with nanotechnology and biotechnology, she contributes to the development of innovative therapeutic platforms with translational healthcare significance. Her interdisciplinary research approach continues advancing pharmaceutical innovation and expanding opportunities in biomedical therapeutics and personalized medicine.

Award and Honor

Dr. Hatziantoniou has earned significant academic recognition for her impactful contributions to pharmaceutical sciences, nanotechnology, and biomedical therapeutics. Her extensive publication record, strong citation performance, and influential scientific collaborations highlight her reputation within international pharmaceutical research communities. She has contributed to highly regarded journals in pharmaceutics, nanomedicine, and biomedical engineering while participating in innovative healthcare research initiatives. Her achievements in liposomal therapeutics, topical pharmaceutical technology, and cancer nanomedicine demonstrate scientific originality and sustained academic excellence. Through collaborative investigations and advanced therapeutic studies, she has gained recognition for promoting translational pharmaceutical innovation and interdisciplinary biomedical progress. Her professional accomplishments reflect dedication to scientific discovery, mentorship, and the advancement of modern pharmaceutical technologies.

Conclusion

Dr. Sophia Hatziantoniou represents an influential figure in pharmaceutical technology and nanomedicine through her impactful scientific achievements, innovative therapeutic investigations, and interdisciplinary collaborations. Her expertise in drug delivery systems, liposomal formulations, and biomedical nanotechnology has contributed substantially to modern pharmaceutical sciences and translational healthcare innovation. With extensive scholarly influence, remarkable citation performance, and internationally recognized research contributions, she continues advancing therapeutic technologies and biomedical understanding. Her commitment to scientific excellence, mentorship, and collaborative healthcare research positions her as a distinguished academic leader with enduring influence on pharmaceutical innovation, nanotherapeutics, and future biomedical developments worldwide.

Publications Top Noted

  • Title: Nanoliposomes and their applications in food nanotechnology
    Authors: M Reza Mozafari, C Johnson, S Hatziantoniou, C Demetzos
    Year: 2008
    Citation: 938
    Citations: 701
  • Title: Metabolism and anticancer activity of the curcumin analogue, dimethoxycurcumin
    Authors: C Tamvakopoulos, K Dimas, ZD Sofianos, S Hatziantoniou, Z Han
    Year: 2007
    Citation: 238
  • Title: A DSC and Raman spectroscopy study on the effect of PAMAM dendrimer on DPPC model lipid
    Authors: K Gardikis, S Hatziantoniou, K Viras, M Wagner, C Demetzos
    Year: 2006
    Citation: 369
  • Title: lipid analysis of Greek walnut oil (Juglans regia L.)
    Authors: G Tsamouris, S Hatziantoniou, C Demetzos
    Year: 2002
    Citation: 112
  • Title: Cytotoxic and antitumor activity of liposome-incorporated sclareol against cancer cell lines and human colon cancer xenografts
    Authors: S Hatziantoniou, K Dimas, A Georgopoulos, N Sotiriadou, C Demetzos
    Year: 2006
    Citation: 94

Konstantinos avgoustakis | Natural and plant-based skincare ingredients | Research Excellence Award

Posted on by Skincare

Prof. Dr. Konstantinos avgoustakis | Natural and plant-based skincare ingredients | Research Excellence Award

University of Patras, Greece

Konstantinos Avgoustakis is a distinguished researcher recognized for his influential contributions to pharmaceutical nanotechnology, advanced drug delivery systems, and biomaterials engineering. His academic work has significantly advanced the understanding of polymeric nanoparticles, PEGylated nanocarriers, and controlled-release therapeutics for cancer treatment and biomedical applications. Through extensive interdisciplinary collaborations, he has produced highly cited publications in internationally reputed journals, reflecting his expertise in nanomedicine and pharmaceutical sciences. His research emphasizes innovative therapeutic delivery strategies that improve bioavailability, targeting efficiency, and clinical outcomes. With a strong scientific foundation and sustained scholarly productivity, Konstantinos Avgoustakis continues to inspire advancements in pharmaceutical innovation and translational biomedical research worldwide

Professional Profile

Education

Konstantinos Avgoustakis developed a strong academic foundation in pharmaceutical sciences and nanotechnology through advanced scientific training and interdisciplinary research engagement. His educational background fostered deep expertise in polymer chemistry, drug formulation technologies, biomedical engineering, and pharmaceutical innovation. Throughout his academic progression, he concentrated on nanoscale drug delivery systems and the optimization of biodegradable polymers for therapeutic applications. His scholarly preparation enabled him to bridge pharmaceutical sciences with biomedical technology, leading to impactful research in controlled drug release and targeted therapeutics. The rigorous scientific environment in which he trained cultivated analytical thinking, experimental precision, and translational research capabilities. His educational achievements laid the groundwork for his internationally recognized contributions to pharmaceutical nanotechnology and innovative healthcare solutions

Professional Experience

Konstantinos Avgoustakis possesses extensive professional experience in pharmaceutical nanotechnology, drug delivery research, and biomaterials development. Over the years, he has actively contributed to experimental and translational studies focused on nanoparticle engineering, pharmacokinetics, and therapeutic targeting strategies. His work includes the development of PLGA and PEG-based nanocarriers designed to improve the efficacy and stability of anticancer therapeutics. He has collaborated with multidisciplinary research teams, contributing to scientific innovation across pharmaceutical and biomedical disciplines. His experience also encompasses publication leadership, mentoring scientific research activities, and advancing nanoparticle-mediated therapeutic technologies. Through sustained academic productivity and impactful collaborations, he has established a respected presence within the global pharmaceutical research community while continuously supporting advancements in nanomedicine and controlled drug delivery systems

Research Interest

The primary research interests of Konstantinos Avgoustakis center on pharmaceutical nanotechnology, targeted drug delivery, polymeric nanoparticles, and advanced biomedical applications. His investigations focus on the design and optimization of biodegradable nanocarriers capable of enhancing therapeutic efficiency and reducing systemic toxicity. He is particularly interested in PLGA-based nanoparticles, PEGylated systems, anticancer formulations, pharmacokinetic modeling, and controlled-release technologies. His scientific studies explore the interaction between nanomaterials and biological systems to improve precision medicine approaches and therapeutic performance. Additionally, his work examines innovative strategies for improving bioavailability, stability, and cellular targeting of pharmaceutical compounds. Through these research directions, he contributes to the advancement of safer, more effective, and clinically adaptable nanomedicine technologies with broad applications in oncology, pharmaceutical sciences, and biomedical engineering.

Award and Honor

Konstantinos Avgoustakis has earned significant academic recognition for his pioneering research contributions in pharmaceutical nanotechnology and drug delivery sciences. His highly cited publications, strong citation metrics, and international scholarly impact demonstrate sustained excellence in biomedical and pharmaceutical innovation. He is widely acknowledged for advancing nanoparticle-mediated therapeutic systems and improving controlled drug release methodologies for cancer treatment and biomedical applications. His research achievements have enhanced scientific understanding of biodegradable polymers, targeted nanocarriers, and pharmacokinetic optimization. Through influential collaborations and impactful scientific dissemination, he has established a distinguished reputation within the pharmaceutical and nanomedicine research community. His consistent scholarly productivity and innovative scientific vision continue to position him as a respected contributor to global advancements in nanotechnology-driven healthcare and pharmaceutical engineering.

Conclusion

Konstantinos Avgoustakis represents an accomplished scientific researcher whose work has significantly influenced pharmaceutical nanotechnology and advanced drug delivery research. His extensive publication record, strong citation performance, and innovative investigations reflect a deep commitment to improving therapeutic technologies and biomedical applications. By integrating polymer science, nanomedicine, and pharmaceutical engineering, he has contributed to the development of efficient nanoparticle systems for targeted treatment strategies. His scientific contributions continue to support progress in controlled-release therapeutics, precision medicine, and biomedical innovation. Through impactful research, interdisciplinary collaboration, and sustained academic excellence, he remains an influential figure in pharmaceutical sciences. His continued dedication to scientific discovery is expected to further advance nanotechnology-based healthcare solutions and inspire future developments in global biomedical research

Publications Top Noted

  • Title: LGA–mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties
    Authors: K Avgoustakis, A Beletsi, Z Panagi, P Klepetsanis, AG Karydas
    Year: 2002
    Citations: 701
  • Title: Pegylated poly (lactide) and poly (lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery
    Authors: K Avgoustakis
    Year: 2004
    Citation: 585
  • Title: Chitosan nanoparticles loaded with dorzolamide and pramipexole
    Authors: S Papadimitriou, D Bikiaris, K Avgoustakis, E Karavas, M Georgarakis
    Year: 2008
    Citation: 369
  • Title: Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA–mPEG nanoparticles
    Authors: Z Panagi, A Beletsi, G Evangelatos, E Livaniou, DS Ithakissios
    Year: 2001
    Citation: 316
  • Title: Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA–mPEG nanoparticles
    Authors: K Avgoustakis, A Beletsi, Z Panagi, P Klepetsanis, E Livaniou
    Year: 2003
    Citation: 313